Notes
Salvador Romero et al. IPVS 2022
The objective of this study was to analyze the combination of an MLV and a KV (SUIPRAVAC® PRRS, HIPRA) to maintain a high level of immunity against PRRSV in sows and to keep producing quality piglets.
Notes
Salvador Romero et al. IPVS 2022
The objective of this study was to assess the use of a KV in a combined protocol together with a MLV, evaluating the concentration of neutralizing antibodies in colostrum from sows and the stabilization of the piglets’ PRRSv status on PRRS endemic farms.
Notes
Emili Barba-Vidal et al. IPVS 2020
This study aims to evaluate the in vitro viability of a PRRSv live attenuated vaccine after its combination with an inactivated vaccine against Glässer disease.
Notes
Ruangurai Kitchodok et al. IPVS 2020
The aim of this study was to evaluate the safety and efficacy of this combination on commercial swine farms in Thailand.
Notes
Sánchez-Matamoros, A. et al.; Porcine Health Management (2019) 5:11
https://doi.org/10.1186/s40813-019-0118-9
The aim of this study was to evaluate the safety and long-term immunity of the authorized combined administration of a PRRSV MLV vaccine and an inactivated vaccine against porcine parvovirus and Erysipelothrix rhusiopathiae simultaneously used.
Notes
Miranda, J. et al.; ESPHM Congress 2019.
The aim of this study was to assess the dynamics of homologous neutralizing antibodies (NA) against the PRRSV MLV vaccine strain during this immunization schedule are presented.
Notes
Simon-Grifé, M. et al.; IPVS 2018.
It was demonstrated that the association of UNISTRAIN® PRRS and AUSKIPRA® GN administered by the intradermal and the intramuscular routes is as safe and efficacious as the administration of both products separately.
Notes
De Lucas, L et al.; IPVS 2018.
The safety of the combined administration of UNISTRAIN® PRRS and GRIPORK® is confirmed with regard to all the evaluated parameters (local and systemic reactions, rectal temperature and sow reproductive performance).
Notes
Martínez, C. et al.; APVS 2015.
These results suggest there is no interference on PRRSv viability between vaccine components when UNISTRAIN® PRRS is reconstituted with GRIPORK®.
Notes
Camprodon, A. et al.; ESPHM 2015.
The safety of the combined administration of ERYSENG® PARVO and UNISTRAIN® PRRS is confirmed with regard to all the evaluated parameters (local reactions, general clinical signs and body temperature). The combined administration of ERYSENG® PARVO and UNISTRAIN® PRRS did not have any negative effects on the reproductive and farrowing parameters.
Notes
Camprodon, A. et al.; ESPHM 2015.
Vaccination with the combination of ERYSENG® PARVO and UNISTRAIN® PRRS effectively protects animals from transplacental infection caused by PPV.
Notes
Camprodon, A. et al.; ESPHM 2015.
The humoral immunity elicited by the combined administration of ERYSENG® PARVO and UNISTRAIN® PRRS enabled animals to manage the experimental infection, showing a reduction in fever and skin lesions after a challenge with virulent E. rhusiopathiae strains.
Notes
Miranda, J. et al.; ESPHM 2015.
Vaccination with the combined administration of ERYSENG® PARVO and UNISTRAIN® PRRS significantly reduced the percentage of viraemic gilts and the duration of viraemia in gilts after a heterologous PRRS infection. Also, the combined use of the vaccines reduced vertical and horizontal transmission to their piglets. The results obtained allow the conclusion to be drawn that the efficacy in terms of viraemia after a PRRS challenge with the combined use of the two vaccines is comparable to that of UNISTRAIN® PRRS administered alone.
Notes
Miranda, J. et al.; ESPHM 2015.
After gilt infection, piglets from the vaccinated gilts were heavier when weaned and grew faster than piglets from the control gilts. Overall piglet performance was significantly better in piglets born from vaccinated gilts with the combined administration of ERYSENG® PARVO and UNISTRAIN®PRRS.
Notes
Miranda, J. et al.; ESPHM 2015.
The combined administration of ERYSENG® PARVO and UNISTRAIN® PRRS significantly reduced the number of weak piglets and the presence of mummies in vaccinated gilts after a heterologous PRRSv challenge. So the use of the vaccine mixture clinically protected gilts from a heterologous PRRSv infection. The results obtained allow the conclusion to be drawn, that efficacy in terms of clinical protection after a PRRS challenge with the combined use of the two vaccines is comparable to that of UNISTRAIN® PRRS administered alone.
Notes
Miranda, J. et al.; IPVS & ESPHM Congress 2016.
The results of the study demonstrated that the viability of the PRRS virus after mixing UNISTRAIN®PRRS and ERYSENG® PARVO can be guaranteed for 2 hours after reconstitution, unlike the non-registered combination of the other commercial MLV combined with the SE and PPV vaccine from the same manufacturer.
Notes
Miranda, J. et al.; IPVS & ESPHM Congress 2016.
Results of the present study suggest that UNISTRAIN® PRRS administered alone or combined with ERYSENG® PARVO induces a significant specific CMI response against heterologous PRRSV strains after a common vaccination scheme with primary vaccination and revaccination 4 months later.